title: Second-line with paclitaxel and carboplatin for recurrent disease following first paclitaxel and platinum compounds in ovarian carcinoma.
abstract: OBJECTIVE
  The combination of paclitaxel and platinum compounds is considered the best first-line regimen for advanced ovarian carcinoma. The purpose of this study was to evaluate a paclitaxel and carboplatin combination in pretreated patients who recurred within 24 months after a complete clinical response with the same regimen used as first-line chemotherapy.
  
  
  METHODS
  18 patients were included in this study. Second-line chemotherapy consisted of paclitaxel, 175 mg/m2 as a 3-hour infusion, and carboplatin AUC 6 every 21 days.
  
  
  RESULTS
  Among 15 evaluable patients, eight (53%) complete and five (34%) partial responses were observed, while two (13%) patients had stable disease (SD). The response rate was 67% among patients with measurable disease and 52% for evaluable disease. The median progression-free interval after second-line chemotherapy was 8.3 months. The median progression-free interval for patients with measurable disease was 8.6 months and for evaluable disease it was 7.9 months. Seven (46%) of 15 patients have developed recurrence after second-line chemotherapy with paclitaxel and carboplatin with a median time to recurrence of 9.8 months.
  
  
  CONCLUSIONS
  Paclitaxel 175 mg/m2 and carboplatin AUC 6 as second-line chemotherapy in this sensitive population is effective in terms of response rate and progression-free interval.
authors.affiliation: Department of Obstetrics and Gynecology, Second University of Naples, Italy.
authors.forename: G
authors.initials: G
authors.lastname: Balbi
authors.forename: L
authors.initials: L
authors.lastname: Di Prisco
authors.forename: R
authors.initials: R
authors.lastname: Musone
authors.forename: A
authors.initials: A
authors.lastname: Menditto
authors.forename: E
authors.initials: E
authors.lastname: Cassese
authors.forename: C
authors.initials: C
authors.lastname: Balbi
authors.forename: A
authors.initials: A
authors.lastname: Cardone
mesh_terms: D000328:Adult; D000368:Aged; D000971:Antineoplastic Combined Chemotherapy Protocols / Q000627:therapeutic use*; D016190:Carboplatin / Q000008:administration & dosage; D018572:Disease-Free Survival; D004334:Drug Administration Schedule; D005260:Female; D006801:Humans; D007262:Infusions, Intravenous; D008875:Middle Aged; D009364:Neoplasm Recurrence, Local / Q000188:drug therapy* / Q000401:mortality / Q000473:pathology; D009367:Neoplasm Staging; D010051:Ovarian Neoplasms / Q000188:drug therapy* / Q000401:mortality / Q000473:pathology; D017239:Paclitaxel / Q000008:administration & dosage; D010166:Palliative Care; D016896:Treatment Outcome
chemical_list: D016190:Carboplatin; D017239:Paclitaxel